Literature DB >> 18347032

Both CD4+ and CD8+ T cells respond to antigens fused to anthrax lethal toxin.

Christine A Shaw1, Michael N Starnbach.   

Abstract

The lethal toxin produced by Bacillus anthracis is a bipartite toxin in which the first protein, protective antigen (PA), transports the second protein, lethal factor, across the host cell membrane. We have previously shown that CD8(+) T-cell epitopes fused to a nontoxic derivative of lethal factor (LFn) are delivered into the host cell cytosol in a PA-dependent manner. Delivery of these antigens targets them to the intracellular major histocompatibility complex (MHC) class I processing and presentation pathway and leads to the stimulation of antigen-specific CD8(+) T cells in vivo. In this report, we describe the generation and characterization of LFn fusion proteins that include not only a CD8(+) T-cell epitope but also a CD4(+) T-cell epitope. We first show that these fusion proteins induce antigen-specific CD4(+) T-cell responses following incubation with dendritic cells in vitro or injection into mice. Stimulation of CD4(+) T cells by LFn fusion proteins does not require PA but is enhanced by PA in vitro. We also show that a single LFn fusion protein and PA can deliver antigen to both the MHC class II and the MHC class I pathways, resulting in the simultaneous induction of antigen-specific CD4(+) T cells and antigen-specific CD8(+) T cells in the same mouse. These results suggest that this toxin delivery system is capable of stimulating protective immune responses where effective immunization requires stimulation of both classes of T cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347032      PMCID: PMC2423103          DOI: 10.1128/IAI.01718-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax.

Authors:  B R Sellman; M Mourez; R J Collier
Journal:  Science       Date:  2001-04-27       Impact factor: 47.728

2.  Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells.

Authors:  S M Kaech; R Ahmed
Journal:  Nat Immunol       Date:  2001-05       Impact factor: 25.606

Review 3.  CD8+ T cell effector mechanisms in resistance to infection.

Authors:  J T Harty; A R Tvinnereim; D W White
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

4.  Point mutations in anthrax protective antigen that block translocation.

Authors:  B R Sellman; S Nassi; R J Collier
Journal:  J Biol Chem       Date:  2000-12-11       Impact factor: 5.157

Review 5.  Presentation of antigens by MHC class II molecules: getting the most out of them.

Authors:  J A Villadangos
Journal:  Mol Immunol       Date:  2001-09       Impact factor: 4.407

6.  Stoichiometry of anthrax toxin complexes.

Authors:  Jeremy Mogridge; Kristina Cunningham; R John Collier
Journal:  Biochemistry       Date:  2002-01-22       Impact factor: 3.162

7.  Repeated antigen exposure is necessary for the differentiation, but not the initial proliferation, of naive CD4(+) T cells.

Authors:  Marc Bajénoff; Olivier Wurtz; Sylvie Guerder
Journal:  J Immunol       Date:  2002-02-15       Impact factor: 5.422

8.  Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.

Authors:  T J Goletz; K R Klimpel; N Arora; S H Leppla; J M Keith; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

9.  Identification of the cellular receptor for anthrax toxin.

Authors:  K A Bradley; J Mogridge; M Mourez; R J Collier; J A Young
Journal:  Nature       Date:  2001-11-08       Impact factor: 49.962

10.  In vivo priming of CD4 T cells that produce interleukin (IL)-2 but not IL-4 or interferon (IFN)-gamma, and can subsequently differentiate into IL-4- or IFN-gamma-secreting cells.

Authors:  X Wang; T Mosmann
Journal:  J Exp Med       Date:  2001-10-15       Impact factor: 14.307

View more
  4 in total

1.  A dual purpose universal influenza vaccine candidate confers protective immunity against anthrax.

Authors:  Maria T Arévalo; Junwei Li; Diana Diaz-Arévalo; Yanping Chen; Ashley Navarro; Lihong Wu; Yongyong Yan; Mingtao Zeng
Journal:  Immunology       Date:  2016-12-05       Impact factor: 7.397

2.  Modular domain swapping among the bacterial cytotoxic necrotizing factor (CNF) family for efficient cargo delivery into mammalian cells.

Authors:  Elizabeth E Haywood; Mengfei Ho; Brenda A Wilson
Journal:  J Biol Chem       Date:  2018-01-25       Impact factor: 5.157

3.  Receptor-enhanced immunogenicity of anthrax protective antigen is primarily mediated by capillary morphogenesis Protein-2.

Authors:  Anita Verma; Mahtab Moayeri; Christopher P Mocca; Danielle O'Mard; Qian Ma; Stephen H Leppla; Drusilla L Burns
Journal:  Vaccine       Date:  2022-06-14       Impact factor: 4.169

4.  Bacillus anthracis interacts with plasmin(ogen) to evade C3b-dependent innate immunity.

Authors:  Myung-Chul Chung; Jessica H Tonry; Aarthi Narayanan; Nathan P Manes; Ryan S Mackie; Bradford Gutting; Dhritiman V Mukherjee; Taissia G Popova; Fatah Kashanchi; Charles L Bailey; Serguei G Popov
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.